Logo

BeiGene Signs an Exclusive License Agreement with Singlomics for Neutralizing COVID-19 Antibodies

Share this
BeiGene Signs an Exclusive License Agreement with Singlomics for Neutralizing COVID-19 Antibodies

BeiGene Signs an Exclusive License Agreement with Singlomics for Neutralizing COVID-19 Antibodies

Shots:

  • Singlomics to receive upfront and is eligible to receive regulatory & commercial milestones along with royalties on sales of products. BeiGene get an exclusive global right (Ex-China) to develop & commercialize its preclinical assets (DXP-593 and DXP-604)- as well as for a series of Ab sequences targeting COVID-19
  • The companies plan to initiate P-I study enrolling up to 30 healthy subjects in Australia in Sept’2020 and anticipates the initiation of enrollment in P-I/II study in patients with mild to moderate COVID-19 by early Oct’2020
  • DXP-593 and DXP-604 are SARS-CoV-2 neutralizing Ab drug candidates identified by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from over 60 convalescent patients. The candidates elicited strong neutralization potency in its preclinical testing

­ Ref: BeiGene | Image: OutSourcing Pharma

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions